OBJECTIVES: The aims of this study were (1) to determine the incremental information provided by (18)F-FDG positron emission tomography (PET) in staging patients with oesophageal cancer, and (2) to determine the impact of PET staging on post-PET clinical management of oesophageal cancer, and on prognosis. METHODS: In a multicentre, single-arm open study, patients with proved oesophageal cancer without definite distant metastases and regarded as suitable for potentially curative treatment were examined by PET. Clinicians were requested to supply a management plan before and another plan after being supplied with the PET scan results. Patients were followed for at least 1 year for outcome analysis. RESULTS: A total of 129 patients (104 men, mean age 67 y) were recruited. PET detected additional sites of disease in 53 patients (41%). Significant changes in management (high or medium impact) were observed in 38% of patients, primarily as a result of identifying additional sites of disease and/or confirming previously equivocal regional and distant metastases. Progression-free survival was significantly shorter in patients found to have additional lesions on PET (p < 0.05), but was not related to SUV(max). CONCLUSION: These findings demonstrate the significant impact of PET on the clinical management of patients with newly diagnosed oesophageal carcinoma, and on prognostic stratification of these patients.
OBJECTIVES: The aims of this study were (1) to determine the incremental information provided by (18)F-FDG positron emission tomography (PET) in staging patients with oesophageal cancer, and (2) to determine the impact of PET staging on post-PET clinical management of oesophageal cancer, and on prognosis. METHODS: In a multicentre, single-arm open study, patients with proved oesophageal cancer without definite distant metastases and regarded as suitable for potentially curative treatment were examined by PET. Clinicians were requested to supply a management plan before and another plan after being supplied with the PET scan results. Patients were followed for at least 1 year for outcome analysis. RESULTS: A total of 129 patients (104 men, mean age 67 y) were recruited. PET detected additional sites of disease in 53 patients (41%). Significant changes in management (high or medium impact) were observed in 38% of patients, primarily as a result of identifying additional sites of disease and/or confirming previously equivocal regional and distant metastases. Progression-free survival was significantly shorter in patients found to have additional lesions on PET (p < 0.05), but was not related to SUV(max). CONCLUSION: These findings demonstrate the significant impact of PET on the clinical management of patients with newly diagnosed oesophageal carcinoma, and on prognostic stratification of these patients.
Authors: H L van Westreenen; M Westerterp; P M M Bossuyt; J Pruim; G W Sloof; J J B van Lanschot; H Groen; J Th M Plukker Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Henderik L van Westreenen; John T M Plukker; David C P Cobben; Carolien J M Verhoogt; Henk Groen; Pieter L Jager Journal: AJR Am J Roentgenol Date: 2005-08 Impact factor: 3.959
Authors: Bryan F Meyers; Robert J Downey; Paul A Decker; Robert J Keenan; Barry A Siegel; Robert J Cerfolio; Rodney J Landreneau; Carolyn E Reed; Dennis M Balfe; Farrokh Dehdashti; Karla V Ballman; Valerie W Rusch; Joe B Putnam Journal: J Thorac Cardiovasc Surg Date: 2007-03 Impact factor: 5.209
Authors: Trevor Leong; Craig Everitt; Kally Yuen; Sara Condron; Andrew Hui; Samuel Y K Ngan; Alexander Pitman; Eddie W F Lau; Michael MacManus; David Binns; Trevor Ackerly; Rodney J Hicks Journal: Radiother Oncol Date: 2006-03-20 Impact factor: 6.280
Authors: Claire Brown; Ben Howes; Glyn G Jamieson; Dylan Bartholomeusz; Urs Zingg; Thomas R Sullivan; Sarah K Thompson Journal: World J Surg Date: 2012-05 Impact factor: 3.352
Authors: Bruce E Hillner; Tor D Tosteson; Anna N A Tosteson; Qianfei Wang; Yunjie Song; Tracy Onega; Lucy G Hanna; Barry A Siegel Journal: Med Care Date: 2013-04 Impact factor: 2.983
Authors: Bruce E Hillner; Anna N Tosteson; Tor D Tosteson; Qianfei Wang; Yunjie Song; Lucy G Hanna; Barry A Siegel Journal: J Nucl Med Date: 2013-11-12 Impact factor: 10.057
Authors: Omar S Al-Taan; Amar Eltweri; David Sharpe; Peter M Rodgers; Sukhbir S Ubhi; David J Bowrey Journal: World J Gastrointest Oncol Date: 2014-05-15